Key result
Transcatheter edge-to-edge repair (TEER) is a valuable therapeutic option for functional mitral regurgitation, with clinical benefits heavily dependent on appropriate patient selection.
Why the study?
This article seeks to provide an overview and current understanding of the role of transcatheter edge-to-edge repair (TEER) in functional mitral regurgitation.
This review provides an overview of the role of transcatheter edge-to-edge repair (TEER) in managing functional mitral regurgitation in patients with heart failure.
Answers are grounded in this paper and cite their sources.
TEER in functional MR requires rigorous selection; supports refined criteria but leaves open optimal thresholds for broader adoption.
The presence and severity of functional mitral regurgitation (FMR) is associated with worse outcomes in patients with heart failure and reduced ejection fraction. Prior to the availability of percutaneous mitral valve repair, management for FMR has been limited to medical therapy, cardiac resynchronization therapy for a specific subset of patients and surgery which has yet to demonstrate mortality benefits. Transcatheter edge-to-edge repair (TEER) of the mitral valve has emerged in the past decade as an invaluable member of the armamentarium against FMR with the 2 landmark randomized controlled trials providing deep insights on patient selection. In addition, TEER has spurred the rapid advancement in our understanding of FMR. This article seeks to provide an overview as well as our current understanding on the role of TEER in FMR.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2022) conducted a review in Functional mitral regurgitation. Transcatheter edge-to-edge repair (TEER) vs. Medical therapy was evaluated. Transcatheter edge-to-edge repair (TEER) is a valuable therapeutic option for functional mitral regurgitation, with clinical benefits heavily dependent on appropriate patient selection.
Synapse has enriched 10 related papers. Consider them for comparative context: